SCHEMBL16198047

SCHEMBL16198047

O=C(O)NCCSc1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.53
RAB9A P51151 1/20 0.53
LMNA P02545 3/20 0.53
RECQL P46063 1/20 0.52
PRKAG1 P54619 2/20 0.50
PRKAA2 P54646 2/20 0.50
PRKAB1 Q9Y478 2/20 0.50
SMN1; SMN2 Q16637 3/20 0.47
MAPT P10636 6/20 0.47
KMT2A Q03164 4/20 0.47
NPSR1 Q6W5P4 1/20 0.47
POLB P06746 1/20 0.47
MEN1 O00255 3/20 0.46
TSHR P16473 1/20 0.46
ALOX5 P09917 1/20 0.45
CCNK O75909 1/20 0.44
CDK12 Q9NYV4 1/20 0.44
ALDH1A1 P00352 2/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17531755 0.85 SMN1; SMN2 (0.51) HSD17B10RAB9ALMNARECQLSMN1; SMN2
SCHEMBL16198546 0.83 IDO1 (0.49) HSD17B10RAB9ALMNARECQLPRKAG1
SCHEMBL10766914 0.82 BCHE (0.65) RAB9ALMNASMN1; SMN2MAPTKMT2A
SCHEMBL16198281 0.81 SNCA (0.48) HSD17B10RAB9ALMNARECQLSMN1; SMN2
SCHEMBL16198322 0.80 BCHE (0.51) HSD17B10RAB9ALMNARECQLPRKAG1
SCHEMBL17513340 0.78 HTT (0.51) LMNARECQLPRKAG1PRKAA2PRKAB1
SCHEMBL19330527 0.75 CYP1A2 (0.61) RAB9ALMNAMAPTPOLBALDH1A1
SCHEMBL16198369 0.75 SNCA (0.47) RAB9ALMNARECQLSMN1; SMN2MAPT
SCHEMBL17531756 0.74 MPO (0.73) LMNARECQLSMN1; SMN2MAPTKMT2A
SCHEMBL11020969 0.74 RAB9A (0.50) HSD17B10RAB9ALMNARECQLPRKAG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9643933-B2 Compounds useful as antibiotic tolerance inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2017-05-09 US disclosed
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2016-02-25 US disclosed
WO-2014176258-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS THE GENERAL HOSPITAL CORPORATION (US) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052890-A1 COMPOUNDS USEFUL AS ANTIBIOTIC TOLERANCE INHIBITORS CFTR, SLC11A2, MRPS18A HSD17B10 3796/4885RAB9A 713/4885LMNA 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.